Purolite, an Ecolab company, has expanded with a new biologics resin manufacturing facility in Landenberg, PA. The expansion will strengthen the security of supply for global pharmaceutical and biotech customers and support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
“We are excited to announce this new facility, because of what it will mean for our customers and the many healthcare patients around the world who benefit from their innovation. As Purolite continues to grow, we are committed to continued chromatography innovation and dedicated applications support, thus improving the global supply of the high-quality products to produce lifesaving and life-enhancing therapeutics,” said Hayley Crowe, senior vice president and general manager, Purolite.
Plans for the expansion include the construction of resin production facilities, cleanrooms, laboratories, and new office space. Additional land is available at the site for future expansion to meet potential growth needs. The Landenberg facility will be Purolite’s fourth location in the state. The new facility is expected to significantly expand production capacity and add more than 150 skilled jobs in the next five years.
“The Commonwealth of Pennsylvania is home to a growing biotech industry, and with Purolite’s expansion in Chester County, we are cementing ourselves as one of the leaders in this rapidly expanding field,” said Governor Josh Shapiro. “I’m proud that Pennsylvania won this expansion project against other states, and I’m pleased that we will be the home of Purolite’s first U.S. Biologics Division. These types of strategic investments in growing businesses are positioning the Commonwealth as an economic powerhouse, and we will continue to make investments that bring more expansions and good-paying jobs to the Commonwealth.”
The Landenberg location will be Purolite’s sixth manufacturing facility globally. It will produce high-quality agarose chromatography resin for downstream monoclonal antibody and recombinant protein purification, and it will support new modality purification across cell therapy, gene therapy and mRNA.
